Table 1.
R11-SSPEI/miR-29b and Radioresponsiveness of HeLa-R Cells Implanted in Mice Treatment Condition
| Treatmenta | Time to Grow from 5 to 22 mm, Days (mean ± SE) | Absolute Growth Delay (mean ± SE)b | Normalized Growth Delay (mean ± SE)c | Enhancement Factord |
|---|---|---|---|---|
| Vehicle | 23.5 ± 1.1 | – | – | – |
| R11-SSPEI/Scr | 24.4 ± 2.3 | 0.9 ± 1.3 | – | – |
| R11-SSPEI/miR-29b | 25.3 ± 2.5 | 1.8 ± 1.4 | – | – |
| XRT | 29.2 ± 1.5 | 5.7 ± 1.1 | – | – |
| XRT+R11-SSPEI/Scr | 31.1 ± 2.4 | 7.6 ± 1.3 | – | – |
| XRT+R11-SSPEI/miR-29b | 43.6 ± 2.2 | 20.1 ± 1.1 | 18.3 ± 0.3 | 3.2 |
a
Five mice per treatment group.
b
Time (in days) required for tumors to grow from 5 to 22 mm minus time (in days) for tumors to grow from 5 to 22 mm in the untreated control.
c
Time (in days) required for tumors to grow from 5 to 22 mm in the combination treatment group minus time (in days) for tumors to grow from 5 to 22 mm in the R11-SSPEI/miR-29b-only control.
d
Normalized growth delay of combination treatment group divided by the absolute growth delay of the radiation-only control.